

# International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,<sup>1</sup> notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any


person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 58 Prop. INN not later than 28 February 1988.

*The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.*

## Proposed International Nonproprietary Names (Prop. INN): List 58<sup>2</sup>

Proposed International Nonproprietary Name (Latin, English)	Chemical Name or Description, Molecular and Graphic Formulae Chemical Abstracts Service (CAS) registry number
---	--

alaninum alanine	L-alanine C <sub>3</sub> H <sub>7</sub> NO <sub>2</sub> 56-41-7
---------------------	--



Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*, Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw. fr. 6.-); an account of this publication will be found in Annex 2 of the present List. All names from Lists 1-47 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances. Cumulative List No. 6, 1982*, World Health Organization, Geneva (ISBN 92 4 056013 0) (price: Sw. fr. 55.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to April 1982. The printout also indicates in which of the 47 individual lists of proposed names and 21 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.


These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

<sup>1</sup> Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, **60**, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1969, **173**, 10).

<sup>2</sup> Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 6, 1982*.


alonacicum  
alonacic

*N*[[*(2R,4R)*-2-methyl-4-thiazolidinyl]carbonyl]- $\beta$ -alanine, methyl ester  
 $C_9H_{16}N_2O_3S$  105292-70-4




ansoxetinum  
ansoxetine

( $\pm$ )-6-[[ $\alpha$ -[2-(dimethylamino)ethyl]benzyl]oxy]flavone  
 $C_{26}H_{25}NO_3$  79130-64-6




atipamezolum  
atipamezole

4-(2-ethyl-2-indanyl)imidazole  
 $C_{14}H_{16}N_2$  104054-27-5




azithromycinum  
azithromycin

(*2R,3S,4R,5R,8R,10R,11R,12S,13S,14R*)-13-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl- $\alpha$ -*L*-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- $\beta$ -*D*-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one  
 $C_{38}H_{72}N_2O_{12}$  83905-01-5




bamaluzolum  
bamaluzole

4-[(*o*-chlorobenzyl)oxy]-1-methyl-1*H*-imidazo[4,5-*c*]pyridine  
C<sub>14</sub>H<sub>12</sub>ClN<sub>3</sub>O 87034-87-5




benazeprilatam  
benazeprilat

(3*S*)-3-[[[(1*S*)-1-carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid  
C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub> 86541-78-8




benazeprilum  
benazepril

(3*S*)-3-[[[(1*S*)-1-carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, 3-ethyl ester  
C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub> 86541-75-5




bendacololum  
bendacolol

(*αR,α'S,2S,2'R*)-*α,α'*-(iminodimethylene)bis[1,4-benzodioxan-2-methanol]  
C<sub>20</sub>H<sub>23</sub>NO<sub>6</sub> 81703-42-6




benidipinum  
benidipine

(±)-(*R*<sup>\*</sup>)-3-[(*R*<sup>\*</sup>)-1-benzyl-3-piperidyl] methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate  
C<sub>28</sub>H<sub>31</sub>N<sub>3</sub>O<sub>6</sub> 105979-17-7




betiatidum  
betiatide

*N*-[*N*-[*N*-(mercaptoacetyl)glycyl]glycyl]glycine benzoate (ester)  
C<sub>15</sub>H<sub>17</sub>N<sub>3</sub>O<sub>6</sub>S 103725-47-9




brequinarum  
brequinar

6-fluoro-2-(2'-fluoro-4-biphenyl)-3-methyl-4-quinolinecarboxylic acid  
C<sub>23</sub>H<sub>15</sub>F<sub>2</sub>NO<sub>2</sub> 96187-53-0




brolaconazolum  
brolaconazole

(±)-1-(*p*-bromo-β-phenylphenethyl)imidazole  
C<sub>17</sub>H<sub>15</sub>BrN<sub>2</sub> 108894-40-2




clanfenurum  
clanfenur

1-(*p*-chlorophenyl)-3-(6-fluoro-*N,N*-dimethylantraniloyl)urea  
C<sub>16</sub>H<sub>15</sub>ClFN<sub>3</sub>O<sub>2</sub> 51213-99-1




clipoxaminum  
clipoxamine

(±)-(*αR*\*)-3-hydroxy-4-methyl-*α*-[(1*S*\*)-1-[(3-phenylpropyl)amino]ethyl]benzyl  
alcohol  
C<sub>19</sub>H<sub>25</sub>NO<sub>2</sub> 109525-44-2




crisnatolum  
crisnatol

2-[(6-chrysenylmethyl)amino]-2-methyl-1,3-propanediol  
C<sub>23</sub>H<sub>23</sub>NO<sub>2</sub> 96389-68-3




cromakalimum  
cromakalim

(±)-*trans*-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-  
chromancarbonitrile  
C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> 94470-67-4




cysteinum  
cysteine

L-cysteine  
C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>S 52-90-4




dalbraminolum  
dalbraminol

(±)-1-phenoxy-3-[[2-[(1,3,5-trimethylpyrazol-4-yl)amino]ethyl]amino]-2-  
propanol  
C<sub>17</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> 81528-80-5




daptomycinum  
daptomycin

*N*-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-  
aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-*threo*-3-methyl-L-glutamyl-3-  
anthraniloyl-L-alanine, ε<sub>1</sub>-lactone  
C<sub>72</sub>H<sub>107</sub>N<sub>17</sub>O<sub>26</sub> 103060-53-3




denipridum  
denipride

(±)-4-amino-5-nitro-*N*-[1-(tetrahydrofurfuryl)-4-piperidyl]-*o*-anisamide  
C<sub>18</sub>H<sub>26</sub>N<sub>4</sub>O<sub>5</sub> 106972-33-2




derpanicum  
derpanicate

nicotinic acid, tetraester with *N,N'*-[dithiobis(ethyleneiminocarbonyl)-ethylene]bis[*R*]-2,4-dihydroxy-3,3-dimethylbutyramide]  
C<sub>46</sub>H<sub>54</sub>N<sub>8</sub>O<sub>12</sub>S<sub>2</sub> 99518-29-3




doreptidum  
doreptide

(2*S*)-*N*[(*aR*)-*a*-[(carbamoylmethyl)carbamoyl]-*a*-ethylbenzyl]-2-pyrrolidinecarboxamide  
C<sub>17</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub> 90104-48-6




doxacurii chloridum  
doxacurium chloride

(1*R*,2*S*;1*S*,2*R*)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7,8-trimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, succinate (2:1)  
C<sub>56</sub>H<sub>78</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>18</sub> 106819-53-8




efetozolum  
efetozole

(±)-2-methyl-1-(*a*-methylbenzyl)imidazole  
C<sub>12</sub>H<sub>14</sub>N<sub>2</sub> 99500-54-6




epicriptinum  
epicriptine

9,10 $\alpha$ -dihydro-13'-*epi*- $\beta$ -ergocryptine or (13'*R*)-9,10 $\alpha$ -dihydro- $\beta$ -ergocryptine  
C<sub>32</sub>H<sub>43</sub>N<sub>5</sub>O<sub>5</sub> 88660-47-3




fluparoxanum  
fluparoxan

(3*aS*,9*aS*)-5-fluoro-2,3,3*a*,9*a*-tetrahydro-1*H*-[1,4]benzodioxino[2,3-*c*]pyrrole  
C<sub>10</sub>H<sub>10</sub>FNO<sub>2</sub> 105182-45-4




flutemazepamum  
flutemazepam

7-chloro-5-(*o*-fluorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2*H*-1,4-  
benzodiazepin-2-one  
C<sub>16</sub>H<sub>12</sub>ClFN<sub>2</sub>O<sub>2</sub> 52391-89-6




histidinum  
histidine

L-histidine  
C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub> 71-00-1




ibudilastum  
ibudilast

1-(2-isopropylpyrazolo[1,5-*a*]pyridin-3-yl)-2-methyl-1-propanone  
C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O 50847-11-5



idenastum  
idenast

2-[4-[4-(*p*-fluorophenyl)-1-piperazinyl]butyl]-1-(*p*-methoxyphenyl)-3-indazolinone  
C<sub>28</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>2</sub> 108674-88-0




insulinum arginum  
insulin argine

30<sup>a</sup>a-L-arginine-30<sup>b</sup>b-L-arginineinsulin (human)  
C<sub>269</sub>H<sub>407</sub>N<sub>73</sub>O<sub>79</sub>S<sub>6</sub> 68859-20-1


irsogladinum  
irsogladine

2,4-diamino-6-(2,5-dichlorophenyl)-*s*-triazine  
C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub> 57381-26-7




isamolтанum  
isamolтан

(±)-1-(isopropylamino)-3-(*o*-pyrrol-1-ylphenoxy)-2-propanol  
C<sub>16</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub> 55050-95-8




isoleucinum  
isoleucine

L-isoleucine  
C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub> 73-32-5




leucinum  
leucine

L-leucine  
C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub> 61-90-5




levdropropizinum  
levdropropizine

(-)-(S)-3-(4-phenyl-1-piperazinyl)-1,2-propanediol  
C<sub>13</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> 99291-24-4




levomoprololum  
levomoprolol

(-)-(S)-1-(isopropylamino)-3-(*o*-methoxyphenoxy)-2-propanol  
C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub> 77164-20-6




libenzaprilum  
libenzapril

N<sup>2</sup>-[(3S)-1-(carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepin-3-yl]-L-lysine  
C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub> 97878-35-8




linsidominum  
linsidomine

3-morpholinosydnone imine  
C<sub>8</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub> 33876-97-0




lomefloxacinum  
lomefloxacin

(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid  
C<sub>17</sub>H<sub>19</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> 98079-51-7




lysinum  
lysine

L-lysine  
C<sub>6</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> 56-87-1




mirosamicinum  
mirosamicin

14-hydroxymycinamicin I or (-)-(1*R*,2*S*,3*R*,6*E*,8*S*,9*S*,10*S*,12*R*,14*E*,16*S*)-2-[[[(6-deoxy-2,3-di-*O*-methyl-β-*D*-allopyranosyl)oxy]methyl]-3-ethyl-2-hydroxy-8,10,12-trimethyl-9-[[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylohexopyranosyl]oxy]-4,17-dioxabicyclo[14.1.0]heptadeca-6,14-diene-5,13-dione  
C<sub>37</sub>H<sub>61</sub>NO<sub>13</sub> 73684-69-2




mivacurii chloridum  
mivacurium chloride

(*R*)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (*E*)-4-octenedioate (2:1)  
C<sub>58</sub>H<sub>80</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>14</sub> 106861-44-3




montirelinum  
montirelin

*N*-[[[(3*R*,6*R*)-6-methyl-5-oxo-3-thiomorpholinyl]carbonyl]-*L*-histidyl-*L*-prolinamide  
C<sub>17</sub>H<sub>24</sub>N<sub>6</sub>O<sub>4</sub>S 90243-66-6




moveltiprilum  
moveltipril

(-)-1-[(2*S*)-3-mercapto-2-methylpropionyl]-*L*-proline, ester with *N*-(cyclohexylcarbonyl)thio-*D*-alanine  
C<sub>19</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub>S 85856-54-8




naxaprostenum  
naxaprostene

$\alpha$ -[(2*E*,3*aS*,4*R*,5*R*,6*aS*)-4-[(1*E*,3*S*)-3-cyclohexyl-3-hydroxypropenyl]hexahydro-5-hydroxy-2(1*H*)-pentalenyldene]-*m*-toluic acid  
C<sub>25</sub>H<sub>32</sub>O<sub>4</sub> 87269-59-8




neraminolum  
neraminol

(±)-1-(1*H*-indazol-4-yloxy)-3-[[2-(2,6-xylidino)ethyl]amino]-2-propanol  
C<sub>20</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> 86140-10-5




norfloxacinum succinilum  
norfloxacin succinil

7-[4-(3-carboxypropionyl)-1-piperazinyl]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid  
C<sub>20</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>6</sub> 100587-52-8




onapristonum  
onapristone

11β-[*p*-(dimethylamino)phenyl]-17α-hydroxy-17-(3-hydroxypropyl)-13α-estra-4,9-dien-3-one  
C<sub>29</sub>H<sub>39</sub>NO<sub>3</sub> 96346-61-1




ornithinum  
ornithine

L-ornithine  
C<sub>5</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> 70-26-8




orotirelinum  
orotirelin

*N*-[(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide  
 $C_{16}H_{19}N_7O_5$  62305-86-6




palatriginum  
palatrigine

5-amino-6-(2,3-dichlorophenyl)-2,3-dihydro-3-imino-2-isopropyl-*as*-triazine  
 $C_{12}H_{13}Cl_2N_5$  98410-36-7




panomifenum  
panomifene

(*E*)-2-[[2-[*p*-(3,3,3-trifluoro-1,2-diphenylpropenyl)phenoxy]ethyl]amino]ethanol  
 $C_{25}H_{24}F_3NO_2$  77599-17-8




pemedolacum  
pemedolac

(±)-4-benzyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-*b*]indole-1-acetic acid  
 $C_{22}H_{23}NO_3$  103024-44-8




perbufyllinum  
perbufylline

7-[4-[4-(*p*-fluorobenzoyl)piperidino]butyl]theophylline  
 $C_{23}H_{28}FN_5O_3$  110390-84-6




phenylalaninum  
phenylalanine

L-phenylalanine  
 $C_9H_{11}NO_2$  63-91-2




pirazmonamum  
pirazmonam

2-[[[(2-amino-4-thiazolyl)][1-[[[3-(1,4-dihydro-5-hydroxy-4-oxopicolinamido)-2-oxo-1-imidazolidinyl]sulfonyl]carbamoyl]-2-oxo-3-azetidiny]carbamoyl]-methylene]amino]oxy]-2-methylpropionic acid  
 $C_{22}H_{24}N_{10}O_{12}S_2$  108319-07-9




ponalrestatum  
ponalrestat

3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid  
 $C_{17}H_{12}BrFN_2O_3$  72702-95-5



pramipexolum  
pramipexole

(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole  
 $C_{10}H_{17}N_3S$  104632-26-0




prolinum  
proline

L-proline  
 $C_5H_9NO_2$  147-85-3




riloaronum  
rilozarone

1-bromo-2-phenyl-3-indolizinyl 3-chloro-4-[3-(dibutylamino)propoxy]phenyl  
ketone  
 $C_{32}H_{36}BrClN_2O_2$  79282-39-6




romifidinum  
romifidine

2-(2-bromo-6-fluoroanilino)-2-imidazoline  
 $C_9H_9BrFN_3$  65896-16-4



salmisteinum  
salmisteine

*N*-acetyl-L-cysteine salicylate (ester), acetate (ester)  
 $C_{14}H_{15}NO_6S$  89767-59-9




saruplasum  
saruplase

prourokinase (enzyme activating) (human clone pUK 4/pUK 18 protein  
moiety reduced)  
 $C_{2031}H_{3145}N_{585}O_{601}S_{31}$  99149-95-8


sematilidum  
sematilide

*N*-[2-(diethylamino)ethyl]-*p*-methanesulfonamidobenzamide  
 $C_{14}H_{23}N_3O_3S$  101526-83-4




serinum  
serine

L-serine  
 $C_3H_7NO_3$  56-45-1




sevopramidum  
sevopramide

(±)-*α*-benzamido-*p*-[3-(diethylamino)propoxy]-*N,N*-dipropylhydro-  
cinnamamide  
C<sub>29</sub>H<sub>43</sub>N<sub>3</sub>O<sub>3</sub> 57227-17-5



simvastatinum  
simvastatin

2,2-dimethylbutyric acid, 8-ester with (4*R*,6*R*)-6-[2-[(1*S*,2*S*,6*R*,8*S*,8*a**R*)-  
1,2,6,7,8,8*a*-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-  
hydroxy-2*H*-pyran-2-one  
C<sub>25</sub>H<sub>36</sub>O<sub>5</sub> 79902-63-9




somidobovum  
somidobove

1-[*N*<sup>2</sup>-[*N*-[*N*-[*N*-[*N*-[1-(*N*-methionyl-L-phenylalanyl)-L-prolyl]-L-leucyl]-L-  
aspartyl]-L-aspartyl]-L-aspartyl]-L-lysine]growth hormone (ox)  
C<sub>1020</sub>H<sub>1596</sub>N<sub>274</sub>O<sub>302</sub>S<sub>9</sub> 89383-13-1


sornidipinum  
sornidipine

(+)-1,4-dihydro-2,6-dimethyl-4-(*o*-nitrophenyl)-3,5-pyridinedicarboxylic acid,  
methyl ester, 5-ester with 1,4: 3,6-dianhydro-*D*-glucitol  
C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>9</sub> 95105-77-4



spirofyllinum  
spirofylline

8-phenethyl-3-[(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxapurin-7-yl)acetyl]-1-  
oxa-3,8-diazaspiro[4,5]decan-2-one  
C<sub>24</sub>H<sub>28</sub>N<sub>6</sub>O<sub>5</sub> 98204-48-9




sudismasum  
sudismase

*N*-acetylsuperoxide dismutase (human clone pS 61-10 copper-zinc subunit protein moiety reduced)  
 $C_{681}H_{1067}N_{203}O_{225}S_4$  110294-55-8


taprostenum  
taprostene

$\alpha$ -[(2*Z*,3*aR*,4*R*,5*R*,6*aS*)-4-[(1*E*,3*S*)-3-cyclohexyl-3-hydroxypropenyl]hexahydro-5-hydroxy-2*H*-cyclopenta[*b*]furan-2-ylidene]-*m*-toluic acid  
 $C_{24}H_{30}O_5$  108945-35-3




taurinum  
taurine

taurine  
 $C_2H_7NO_3S$  107-35-7




temafloxacinum  
temafloxacin

(±)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid  
 $C_{21}H_{18}F_3N_3O_3$  108319-06-8




tepoaxalinum  
tepoaxalin

5-(*p*-chlorophenyl)-1-(*p*-methoxyphenyl)-*N*-methylpyrazole-3-propionhydroxamic acid  
 $C_{20}H_{20}ClN_3O_3$  103475-41-8




texacromilum  
texacromil

(±)-5-[2-hydroxy-3-(methylthio)propoxy]-4-oxo-4*H*-1-benzopyran-2-carboxylic acid  
 $C_{14}H_{14}O_6S$  77005-28-8




threoninum  
threonine

L-threonine  
C<sub>4</sub>H<sub>9</sub>NO<sub>3</sub> 72-19-5




tibenelastum  
tibenelast

5,6-diethoxybenzo[*b*]thiophene-2-carboxylic acid  
C<sub>13</sub>H<sub>14</sub>O<sub>4</sub>S 97852-72-7




traboxopinum  
traboxopine

(±)-2-chloro-12-[3-(dimethylamino)-2-methylpropyl]-12*H*-dibenzo[*d,g*][1,3,6]-  
dioxazine  
C<sub>19</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>2</sub> 103624-59-5




tryptophanum  
tryptophan

L-tryptophan  
C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> 73-22-3




tyrosinum  
tyrosine

L-tyrosine  
C<sub>9</sub>H<sub>11</sub>NO<sub>3</sub> 60-18-4




ufiprazolum  
ufiprazole

5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole  
C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S 73590-85-9




valinum  
valine

L-valine  
 $C_5H_{11}NO_2$  72-18-4




vapiprostum  
vapiprost

(+)-(Z)-7-[(1*R*,2*R*,3*S*,5*S*)-3-hydroxy-5-[(*p*-phenylbenzyl)oxy]-2-piperidinocyclopentyl]-4-heptenoic acid  
 $C_{30}H_{39}NO_4$  85505-64-2



zabiciprilum  
zabicipril

(3*S*)-2-[(2*S*)-*N*[(1*S*)-1-carboxy-3-phenylpropyl]alanyl]-2-azabicyclo[2.2.2]octane-3-carboxylic acid, 1-ethyl ester  
 $C_{23}H_{32}N_2O_5$  83059-56-7



### Names for Radicals and Groups


Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved

may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals

and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names.

proxetilum  
proxetil

1-[(isopropoxycarbonyl)oxy]ethyl



**AMENDMENTS  
TO PREVIOUS LISTS**

Cumulative List No. 6, 1982

**International Nonproprietary Names (INN) for Pharmaceutical Substances**

	<i>delete</i>	<i>insert</i>
p. 4	acidum aminoaceticum aminoacetic acid	glycinum glycine

WHO Chronicle, Vol. 26, No. 4

**Proposed International Nonproprietary Names (Prop. INN): List 27**

	<i>delete</i>	<i>insert</i>
p. 131	glipentidum glipentide	glisentidum glisentide

Supplement to Vol. 38, No. 4, 1984


**Proposed International Nonproprietary Names (Prop. INN): List 52**

	<i>delete</i>	<i>insert</i>
p. 7	decapinolum decapinol	delmopinolum delmopinol

Supplement to Vol. 40, No. 5, 1986

**Proposed International Nonproprietary Names (Prop. INN): List 56**


p. 1	acidum piridronicum piridronic acid	<i>replace graphic formula by:</i>
------	--	------------------------------------



p. 4	cefempidonum cefempidone	<i>in the graphic formula complete the pyridinio ring with a double bond</i>
p. 7	erythromycini stinopras erythromycin stinoprate	<i>replace the comma between the two graphic formulas by a dot</i>
	famiraprinum famiraprine	<i>delete the whole entry</i>

*insert*  
famiraprinii chloridum  
famiraprinium chloride


6-amino-1-(3-carboxypropyl)-5-methyl-3-phenylpyridazinium chloride  
C<sub>15</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2</sub> 108894-41-3



- p. 13 pentiapinum  
pentiapine  
p. 18 triptorelinum  
triptorelin

*in the graphic formula complete the benzene ring with a double bond*

*replace the graphic formula by the following:*




WHO Drug Information, Vol. 1, No. 2, 1987

### Proposed International Nonproprietary Names (Prop. INN): List 57

- p. 93 cefpodoximum  
cefpodoxime

*replace chemical name, CAS reg. no., molecular formula and graphic formula by:*

(+)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7<sup>2</sup>-(*Z*)-(O-methyloxime)  
C<sub>15</sub>H<sub>17</sub>N<sub>5</sub>O<sub>6</sub>S<sub>2</sub> 80210-62-4



- p. 100 lacidipinum  
lacidipine

*replace CAS reg. no. by: 103890-78-4*

- p. 110 ademetoninum  
ademetonine

*at the beginning of the chemical name replace (+) by: (±)*

- p. 111 *Before the entries for tetronasinum and omoconazolum insert reference to:*

Supplement to Vol. 40, No. 5, 1986, Proposed International Names (Prop. INN): List 56

- p. 111 omoconazolum  
omoconazole

*reinstate CAS reg. no. 74512-12-2 given in List 45 Prop. INN*

### Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN-lists only.